Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cetuximab monotherapy or in combination with irinotecan for treatment of irinotecan-refractory metastatic colorectal cancer

Reporting in the latest issue of the New England Journal of Medicine, researchers have tested the efficacy of the monoclonal antibody cetuximab, either alone or in combination with a first line therapy, as a treatment in metastatic colorectal cancer.

News image

fiogf49gjkf04

Irinotecan is a first-line treatment for colorectal cancer that, along with other therapies, has helped increase the median survival among colorectal cancer patients from 12 months to about 18 to 21 months over the 10 years.

However, some patients do not respond to treatment with irinotecan and so other therapies are required for such patients.

A research team from hospitals across Europe has therefore investigated the use of cetuximab, a monoclonal antibody that binds with high specificity to the epidermal growth factor receptor (EGFR).

This receptor is of relevance in colorectal cancer because in up to 80% of patients with colorectal cancer, there is up-regulation and expression of the EGFR gene. Furthermore, expression of the gene has been shown to be associated with poor survival.

Through binding of its ligand (epidermal growth factor, or transforming growth factor-) EGFR is involved in signaling pathways that become deregulated in cancer cells, including cell differentiation, proliferation, migration, angiogenesis and apoptosis.

Cetuximab has clinically significant activity in patients with irinotecan-refractory colorectal cancer
New England Journal of Medicine

By binding to EGFR, cetuximab blocks activation of these signaling pathways, thus helping to control the cancerous activities of the cells on which EGFR is expressed. In addition, cetuximab has also been shown in experimental systems to enhance the effects of irinotecan and radiotherapy.

Led by Dr David Cunningham, from the Royal Marsden Hospital, in Surrey, England, the research team compared the efficacy of cetuximab alone with that of cetuximab in combination with irinotecan in patients with metastatic colorectal cancer that was refractory to treatment with irinotecan.

329 patients whose disease had progressed during or within 3 months after treatment with an irinotecan-based regimen were randomly assigned to receive either cetuximab and irinotecan (218 patients) or cetuximab monotherapy (111 patients).

Cetuximab was administered at an initial dose of 400 mg/m2, followed by weekly infusions of 250 mg/m2, while patients receiving the combination therapy received their irinotecan at the same dose and schedule as that given during their most recent prestudy therapy.

In cases of disease progression, the addition of irinotecan to cetuximab monotherapy was permitted.

Tumor response was evaluated every 6 weeks for the first 24 weeks and then at 3 month intervals, using either CT or MRI scans.

Each patient was evaluated radiologically for tumor response and was also evaluated for the time to tumor progression, survival and side-effects of treatment.

Patients receiving the combination therapy were found to respond at a significantly higher rate than those in the monotherapy cohort (22.9% compared to 10.8%).

The median time to progression was also significantly greater in the combination therapy group (4.1 compared to 1.5 months in the monotherapy group).

The median survival time was 8.6 months in the combination therapy group and 6.9 months in the monotherapy group.

However, toxic effects were more frequent in the combination-therapy group, but their severity and incidence were similar to those that would be expected with irinotecan alone.

Commenting on their findings, Dr Cunningham said that the observed tumor-response rate of 22.9% in the combination therapy group was clinically important, since after the standard drugs (including irinotecan) have failed, there are no accepted treatment options.

"Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer," he concluded.

N Engl J Med 2004; 351 (4): 337 - 345
23 July 2004

Go to top of page Email this page Email this page to a colleague

 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us